首页 > 最新文献

Integrative Cancer Therapies最新文献

英文 中文
Hu-Qi-Zheng-Xiao Decoction Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Suppressing the HIF-1α Signaling Pathway to Inhibit EMT, LCSC, and Angiogenic Process. 藿香正气水通过抑制HIF-1α信号通路来抑制EMT、LCSC和血管生成过程,从而抑制肝细胞癌细胞的转移
IF 2.9 3区 医学 Q1 Medicine Pub Date : 2024-01-01 DOI: 10.1177/15347354231226126
Xuejing Wang, Ling Yin, Mengyin Chai, Buxin Kou, Xiaoni Liu, Xiaojun Wang

Background: Hepatocellular carcinoma (HCC) is a common clinical malignant tumor of the digestive system. Hu-Qi-Zheng-Xiao (HQZX) decoction has been clinically found to prolong the survival of patients with hepatocellular carcinoma and improve the quality of patients' survival, but its antitumor biological mechanism is still unclear.

Methods: A nude mouse hollow fiber hepatocellular carcinoma model was constructed to analyze the in vivo efficacy of HQZX decoction against 7 different hepatocellular carcinoma cells. The subcutaneous graft tumor model was again validated. In vitro, the effect of HQZX decoction on the growth and metastasis of the cell line with the highest growth inhibition was evaluated. The cell line with the best efficacy response screened was again used to construct a hollow fiber hepatocellular carcinoma model and hollow fiber conduit cells were extracted to detect the expression of HIF-1α, VEGF, EMT-related molecules, LCSCs-related molecules, and to observe the density of the subcutaneous vascular network of hollow fiber conduits. The liver metastasis model of splenic injection was constructed to observe the effect of HQZX decoction on tumor metastasis.

Results: The hollow fiber hepatocellular carcinoma model was evaluated for the efficacy of HQZX decoction, and it was found to have the highest growth inhibition of LM3-luc cells. In vitro, the CCK8 assay revealed that HQZX decoction could inhibit tumor migration and invasion and promote apoptosis. In addition, the mechanism study of extracting cells from hollow fiber tubes found that HQZX decoction could inhibit metastasis-associated HIF-1α, VEGF, EMT-related molecules, and LCSCs-related molecules expression. capillary network around subcutaneous fiber tubes was reduced in the HQZX decoction gavage group of mice. It inhibited tumor metastasis in nude mice.

Conclusions: HQZX decoction inhibited the growth of a variety of hepatocellular carcinoma cells. HQZX decoction suppressed the expression of metastasis-associated VEGF, EMT-related molecules, and LCSCs-related molecules and inhibited tumor angiogenesis and growth and metastasis, which may be related to the inhibition of the HIF-1α signaling pathway. It reveals that HQZX decoction may be a promising herbal compound for anti-HCC therapy, and also reveals the accurate feasibility of the hollow fiber hepatocellular carcinoma model for in vivo pharmacodynamic evaluation and mechanism study.

背景:肝细胞癌(HCC)是临床上常见的消化系统恶性肿瘤:肝细胞癌(HCC)是临床上常见的消化系统恶性肿瘤。临床发现,藿香正气水能延长肝细胞癌患者的生存期,改善患者的生存质量,但其抗肿瘤的生物学机制尚不清楚:方法:构建裸鼠中空纤维肝癌模型,分析HQZX煎剂对7种不同肝癌细胞的体内疗效。再次验证了皮下移植肿瘤模型。在体外,评估了 HQZX 水煎剂对生长抑制率最高的细胞系的生长和转移效果。再次用筛选出的疗效反应最好的细胞系构建中空纤维肝癌模型,提取中空纤维导管细胞,检测HIF-1α、VEGF、EMT相关分子、LCSCs相关分子的表达,并观察中空纤维导管皮下血管网的密度。构建脾脏注射肝转移模型,观察HQZX煎剂对肿瘤转移的影响:结果:在中空纤维肝癌模型中,HQZX煎剂对LM3-luc细胞的生长抑制率最高。体外CCK8检测显示,HQZX煎剂能抑制肿瘤的迁移和侵袭,并促进细胞凋亡。此外,从空心纤维管中提取细胞的机理研究发现,HQZX煎剂能抑制转移相关的HIF-1α、血管内皮生长因子、EMT相关分子和LCSCs相关分子的表达。结论:HQZX煎剂能抑制裸鼠肿瘤转移:结论:HQZX 水煎剂能抑制多种肝癌细胞的生长。结论:HQZX煎剂可抑制多种肝癌细胞的生长,抑制转移相关的VEGF、EMT相关分子和LCSCs相关分子的表达,抑制肿瘤血管生成和生长转移,可能与抑制HIF-1α信号通路有关。该研究揭示了HQZX水煎剂可能是一种很有前景的抗肝癌中药复方制剂,同时也揭示了中空纤维肝癌模型用于体内药效学评价和机制研究的准确可行性。
{"title":"Hu-Qi-Zheng-Xiao Decoction Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Suppressing the HIF-1α Signaling Pathway to Inhibit EMT, LCSC, and Angiogenic Process.","authors":"Xuejing Wang, Ling Yin, Mengyin Chai, Buxin Kou, Xiaoni Liu, Xiaojun Wang","doi":"10.1177/15347354231226126","DOIUrl":"10.1177/15347354231226126","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a common clinical malignant tumor of the digestive system. Hu-Qi-Zheng-Xiao (HQZX) decoction has been clinically found to prolong the survival of patients with hepatocellular carcinoma and improve the quality of patients' survival, but its antitumor biological mechanism is still unclear.</p><p><strong>Methods: </strong>A nude mouse hollow fiber hepatocellular carcinoma model was constructed to analyze the in vivo efficacy of HQZX decoction against 7 different hepatocellular carcinoma cells. The subcutaneous graft tumor model was again validated. In vitro, the effect of HQZX decoction on the growth and metastasis of the cell line with the highest growth inhibition was evaluated. The cell line with the best efficacy response screened was again used to construct a hollow fiber hepatocellular carcinoma model and hollow fiber conduit cells were extracted to detect the expression of HIF-1α, VEGF, EMT-related molecules, LCSCs-related molecules, and to observe the density of the subcutaneous vascular network of hollow fiber conduits. The liver metastasis model of splenic injection was constructed to observe the effect of HQZX decoction on tumor metastasis.</p><p><strong>Results: </strong>The hollow fiber hepatocellular carcinoma model was evaluated for the efficacy of HQZX decoction, and it was found to have the highest growth inhibition of LM3-luc cells. In vitro, the CCK8 assay revealed that HQZX decoction could inhibit tumor migration and invasion and promote apoptosis. In addition, the mechanism study of extracting cells from hollow fiber tubes found that HQZX decoction could inhibit metastasis-associated HIF-1α, VEGF, EMT-related molecules, and LCSCs-related molecules expression. capillary network around subcutaneous fiber tubes was reduced in the HQZX decoction gavage group of mice. It inhibited tumor metastasis in nude mice.</p><p><strong>Conclusions: </strong>HQZX decoction inhibited the growth of a variety of hepatocellular carcinoma cells. HQZX decoction suppressed the expression of metastasis-associated VEGF, EMT-related molecules, and LCSCs-related molecules and inhibited tumor angiogenesis and growth and metastasis, which may be related to the inhibition of the HIF-1α signaling pathway. It reveals that HQZX decoction may be a promising herbal compound for anti-HCC therapy, and also reveals the accurate feasibility of the hollow fiber hepatocellular carcinoma model for in vivo pharmacodynamic evaluation and mechanism study.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354231226126"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139931037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of a Mindfulness-Based Intervention on Event-Related Potentials (P3) and Depressive Symptoms in Oncological Patients. 基于正念的干预对肿瘤患者事件相关电位(P3)和抑郁症状的影响
IF 2.9 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-01-01 DOI: 10.1177/15347354241294057
Theresa Schweig, Madeleine Fink, Kira Schmidt, Marvin Krawutschke, Saskia Pasche, Eva-Maria Skoda, Martin Teufel, Bernhard W Müller

Objective: The aim of this study was to investigate changes in P3 amplitude and latency to emotional stimuli with different arousal and valence levels after a mindfulness-based intervention in oncological patients. Methods: P3 amplitude and latency at Fz, Cz, and Pz to emotional salient stimuli differing in valence (positive vs. negative) and arousal (low vs. high) levels were measured in 17 oncological patients (Mage = 51 years, SD = 9.17, females = 11) before and after a mindfulness-based intervention in a waitlist-controlled clinical trial. Group sessions were held 2x/week over a period of 5 weeks. Results: Arousal and valence levels of emotional salient stimuli were significant modulators of P3 amplitudes (P = .050; P = .006, respectively). P3 amplitudes at Fz decreased significantly from pre-waitlist to post-intervention (P = .002). P3 latency for negatively valenced stimuli decreased from pre- to post-intervention with trending significance (P = .080). P3 latency at Pz showed a trend of being shorter than P3 latency at Cz (P = .066). Depressive symptoms showed a decreasing trend from pre- to post-treatment (P = .075). Conclusions: We could show that arousal and valence levels of emotional salient stimuli are important modulators of P3 amplitudes and latencies in oncological patients. P3 amplitudes at Fz decreased significantly from pre-waitlist until after mindfulness-based intervention, decreases from pre-to post-intervention were linear, but not significant. In oncological patients the mindfulness-based intervention seems to have its strongest effect on the frontal electrode Fz, not the electrode Pz where its amplitude was largest. Depressive symptoms could be reduced.

目的:研究肿瘤患者正念干预后P3振幅和潜伏期对不同唤醒和效价水平情绪刺激的变化。方法:在一项候补对照临床试验中,对17例肿瘤患者(年龄为51岁,SD = 9.17,女性= 11)进行正念干预前后,测量了不同效价(正、负)和觉醒(低、高)水平的情绪显著刺激在Fz、Cz和Pz的P3振幅和潜伏期。小组会议每周举行2次,为期5周。结果:情绪显著刺激的唤醒和效价水平是P3振幅的显著调节因子(P = 0.050;p =。006年,分别)。P3在Fz的振幅从候补名单前到干预后显著下降(P = 0.002)。负效刺激的P3潜伏期从干预前到干预后下降,具有趋势显著性(P = 0.080)。Pz处P3潜伏期有短于Cz处P3潜伏期的趋势(P = 0.066)。治疗前后抑郁症状呈下降趋势(P = 0.075)。结论:情绪显著刺激的唤醒和效价水平是肿瘤患者P3波幅和潜伏期的重要调节因子。P3在Fz的振幅从候补前到正念干预后显著下降,从干预前到干预后呈线性下降,但不显著。在肿瘤患者中,以正念为基础的干预似乎对额叶电极Fz有最强的影响,而不是其振幅最大的电极Pz。抑郁症状可以减轻。
{"title":"Effects of a Mindfulness-Based Intervention on Event-Related Potentials (P3) and Depressive Symptoms in Oncological Patients.","authors":"Theresa Schweig, Madeleine Fink, Kira Schmidt, Marvin Krawutschke, Saskia Pasche, Eva-Maria Skoda, Martin Teufel, Bernhard W Müller","doi":"10.1177/15347354241294057","DOIUrl":"10.1177/15347354241294057","url":null,"abstract":"<p><p><b>Objective:</b> The aim of this study was to investigate changes in P3 amplitude and latency to emotional stimuli with different arousal and valence levels after a mindfulness-based intervention in oncological patients. <b>Methods:</b> P3 amplitude and latency at Fz, Cz, and Pz to emotional salient stimuli differing in valence (positive vs. negative) and arousal (low vs. high) levels were measured in 17 oncological patients (<i>M<sub>age</sub></i> = 51 years, SD = 9.17, females = 11) before and after a mindfulness-based intervention in a waitlist-controlled clinical trial. Group sessions were held 2x/week over a period of 5 weeks. <b>Results:</b> Arousal and valence levels of emotional salient stimuli were significant modulators of P3 amplitudes (<i>P</i> = .050; <i>P</i> = .006, respectively). P3 amplitudes at Fz decreased significantly from pre-waitlist to post-intervention (<i>P</i> = .002). P3 latency for negatively valenced stimuli decreased from pre- to post-intervention with trending significance (<i>P</i> = .080). P3 latency at Pz showed a trend of being shorter than P3 latency at Cz (<i>P</i> = .066). Depressive symptoms showed a decreasing trend from pre- to post-treatment (<i>P</i> = .075). <b>Conclusions:</b> We could show that arousal and valence levels of emotional salient stimuli are important modulators of P3 amplitudes and latencies in oncological patients. P3 amplitudes at Fz decreased significantly from pre-waitlist until after mindfulness-based intervention, decreases from pre-to post-intervention were linear, but not significant. In oncological patients the mindfulness-based intervention seems to have its strongest effect on the frontal electrode Fz, not the electrode Pz where its amplitude was largest. Depressive symptoms could be reduced.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241294057"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Decoctions Based on Qi-Yin Syndrome Differentiation After Adjuvant Chemotherapy in Resected Stage ΙΙΙA Non-Small Cell Lung Cancer: A Randomized Controlled Trial. 非小细胞肺癌ΙΙA期辅助化疗后根据气阴两虚辨证论治的口服中药:随机对照试验
IF 2.9 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-01-01 DOI: 10.1177/15347354241268271
Yi Jiang, Fang-Fang Liu, Yu-Qing Cai, Peng Zhang, Xiao-Feng Yang, Xiang-Yan Bi, Ruo-Yan Qin, Shi Zhang, Ju-Hua Yin, Li-Ping Shen, Jia-Xiang Liu, Ling-Shuang Liu

Objective: Powerful adjuvant strategies are required to improve the survival of patients with completely resected stage ΙΙΙA non-small cell lung cancer (NSCLC). We aimed to compare the efficacy of traditional Chinese medicine (TCM) treatment versus observation after adjuvant chemotherapy in these patients.

Methods: Eligible patients were randomized 1:1 to receive either oral decoctions based on Qi-Yin syndrome differentiation (TCM group) or observation (observation group). The intervention lasted for 12 months. The primary endpoint was 1-year disease-free survival (DFS). Secondary endpoints were DFS, quality of life, regulatory T cells (Tregs), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on the surface of Tregs in peripheral blood. We used EORTC QLQ-LC43 to evaluate quality of life.

Results: Between Apr 29, 2019, and Nov 11, 2021, 75 patients were randomly assigned to oral decoctions based on Qi-Yin syndrome differentiation (n = 38) or observation (n = 37). The full analysis set included 35 patients in the TCM group and 35 in the observation group. After a median follow-up of 24.2 months, oral decoctions based on Qi-Yin syndrome differentiation improved DFS compared with observation (HR 0.378, 95% CI: 0.157-0.912; P = .03). One-year DFS was 82.1% in the TCM group and 61.9% in the observation group (P = .06). Three months after randomization, scores of total health, role function, emotional function, and social function in the TCM group were higher than those in the observation group (P < .01 for all), scores of fatigue, pain, insomnia, appetite loss, constipation, cough, and chest pain were lower than those in the observation group (P < .05 for all); there was no significant difference in the proportion of Tregs between the TCM group and the observation group (P = .58); the proportion of CTLA-4+Tregs in the TCM group was lower than that in the observation group (P = .046). There were no adverse events that occurred in both groups.

Conclusions: Oral decoctions based on Qi-Yin syndrome differentiation after adjuvant chemotherapy prolonged DFS, reduced the risk of disease recurrence and metastasis, improved quality of life, and down-regulated the proportion of CTLA-4+Tregs in completely resected stage ΙΙΙA NSCLC patients.

Trial registration: Chinese Clinical Trial Register, No. ChiCTR1800019396. Date of registration: 9 November 2018.

目的:要提高完全切除的ΙΙΙA期非小细胞肺癌(NSCLC)患者的生存率,需要强有力的辅助策略。我们的目的是比较这些患者在辅助化疗后接受中医治疗与观察的疗效:符合条件的患者按 1:1 随机分配,接受根据气阴两虚分型的口服煎剂(中医组)或观察(观察组)。干预持续 12 个月。主要终点是1年无病生存期(DFS)。次要终点为DFS、生活质量、调节性T细胞(Tregs)和外周血中Tregs表面的细胞毒性T淋巴细胞相关抗原-4(CTLA-4)。我们使用EORTC QLQ-LC43评估生活质量:2019年4月29日至2021年11月11日期间,75名患者被随机分配到基于气阴两虚综合征分型的口服煎剂(n = 38)或观察(n = 37)。完整的分析集包括中药组和观察组各35名患者。中位随访24.2个月后,与观察组相比,基于气阴两虚证分型的口服煎药改善了DFS(HR 0.378,95% CI:0.157-0.912;P = .03)。中药组的一年 DFS 为 82.1%,观察组为 61.9%(P = .06)。随机分组三个月后,中医治疗组的总体健康、角色功能、情感功能和社会功能评分均高于观察组(P P = .58);中医治疗组的 CTLA-4+Tregs 比例低于观察组(P = .046)。两组患者均未出现不良反应:结论:辅助化疗后口服 "芪阴分型汤 "可延长完全切除ΙΙA期NSCLC患者的DFS,降低疾病复发和转移的风险,改善生活质量,并下调CTLA-4+Tregs的比例:中国临床试验注册,编号:ChiCTR1800019396。注册日期:2018年11月9日。
{"title":"Oral Decoctions Based on Qi-Yin Syndrome Differentiation After Adjuvant Chemotherapy in Resected Stage ΙΙΙA Non-Small Cell Lung Cancer: A Randomized Controlled Trial.","authors":"Yi Jiang, Fang-Fang Liu, Yu-Qing Cai, Peng Zhang, Xiao-Feng Yang, Xiang-Yan Bi, Ruo-Yan Qin, Shi Zhang, Ju-Hua Yin, Li-Ping Shen, Jia-Xiang Liu, Ling-Shuang Liu","doi":"10.1177/15347354241268271","DOIUrl":"10.1177/15347354241268271","url":null,"abstract":"<p><strong>Objective: </strong>Powerful adjuvant strategies are required to improve the survival of patients with completely resected stage ΙΙΙA non-small cell lung cancer (NSCLC). We aimed to compare the efficacy of traditional Chinese medicine (TCM) treatment versus observation after adjuvant chemotherapy in these patients.</p><p><strong>Methods: </strong>Eligible patients were randomized 1:1 to receive either oral decoctions based on Qi-Yin syndrome differentiation (TCM group) or observation (observation group). The intervention lasted for 12 months. The primary endpoint was 1-year disease-free survival (DFS). Secondary endpoints were DFS, quality of life, regulatory T cells (Tregs), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on the surface of Tregs in peripheral blood. We used EORTC QLQ-LC43 to evaluate quality of life.</p><p><strong>Results: </strong>Between Apr 29, 2019, and Nov 11, 2021, 75 patients were randomly assigned to oral decoctions based on Qi-Yin syndrome differentiation (n = 38) or observation (n = 37). The full analysis set included 35 patients in the TCM group and 35 in the observation group. After a median follow-up of 24.2 months, oral decoctions based on Qi-Yin syndrome differentiation improved DFS compared with observation (HR 0.378, 95% CI: 0.157-0.912; <i>P</i> = .03). One-year DFS was 82.1% in the TCM group and 61.9% in the observation group (<i>P</i> = .06). Three months after randomization, scores of total health, role function, emotional function, and social function in the TCM group were higher than those in the observation group (<i>P</i> < .01 for all), scores of fatigue, pain, insomnia, appetite loss, constipation, cough, and chest pain were lower than those in the observation group (<i>P</i> < .05 for all); there was no significant difference in the proportion of Tregs between the TCM group and the observation group (<i>P</i> = .58); the proportion of CTLA-4<sup>+</sup>Tregs in the TCM group was lower than that in the observation group (<i>P</i> = .046). There were no adverse events that occurred in both groups.</p><p><strong>Conclusions: </strong>Oral decoctions based on Qi-Yin syndrome differentiation after adjuvant chemotherapy prolonged DFS, reduced the risk of disease recurrence and metastasis, improved quality of life, and down-regulated the proportion of CTLA-4<sup>+</sup>Tregs in completely resected stage ΙΙΙA NSCLC patients.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Register, No. ChiCTR1800019396. Date of registration: 9 November 2018.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241268271"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic and Additive Effects of Herbal Medicines in Combination with Chemotherapeutics: A Scoping Review. 中草药与化疗药物联用的协同效应和相加效应:范围综述》。
IF 2.9 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-01-01 DOI: 10.1177/15347354241259416
Taehun Jung, Chunhoo Cheon

Background: Natural products are increasingly gaining interest as potential new drug candidates for cancer treatment. Herbal formula, which are combinations of several herbs, are primarily used in East Asia and have a long history of use that continues today. Recently, research exploring the combination of herbal formulas and chemotherapy for cancer treatment has been on the rise.

Methods: This study reviewed research on the co-administration of herbal formulas and chemotherapy for cancer treatment. The databases PubMed, Embase, and Cochrane Library were used for article searches. The following keywords were employed: "Antineoplastic agents," "Chemotherapy," "Phytotherapy," "Herbal medicine," "Drug synergism," and "Synergistic effect." The selection process focused on studies that investigated the synergistic interaction between herbal formulas and chemotherapeutic agents.

Results: Among the 30 studies included, 25 herbal formulas and 7 chemotherapies were used. The chemotherapy agents co-administered included cisplatin, 5-fluorouracil, docetaxel, doxorubicin, oxaliplatin, irinotecan, and gemcitabine. The types of cancer most frequently studied were lung, breast, and colon cancers. Most studies evaluating the anticancer efficacy of combined herbal formula and chemotherapy treatment were conducted in vitro or in vivo.

Discussion: Most studies reported synergistic effects on cytotoxicity, apoptosis, and tumor growth inhibition. These effects were found to be associated with cell cycle arrest, anti-angiogenesis, and gene expression regulation. Further studies leading to clinical trials are required. Clinical experiences in East Asian countries could provide insights for future research.

背景:天然产品作为治疗癌症的潜在候选新药,越来越受到人们的关注。草药配方是几种草药的组合,主要用于东亚地区,其使用历史悠久,一直延续至今。最近,探索中草药配方与化疗相结合治疗癌症的研究正在增加:本研究回顾了有关中草药配方与化疗联合用于癌症治疗的研究。文章检索使用的数据库包括 PubMed、Embase 和 Cochrane Library。关键词如下"抗肿瘤药物"、"化疗"、"植物疗法"、"草药"、"药物协同作用 "和 "协同效应"。筛选过程侧重于调查草药配方与化疗药物之间协同作用的研究:在纳入的 30 项研究中,使用了 25 种草药配方和 7 种化疗药物。共同使用的化疗药物包括顺铂、5-氟尿嘧啶、多西他赛、多柔比星、奥沙利铂、伊立替康和吉西他滨。研究最多的癌症类型是肺癌、乳腺癌和结肠癌。大多数评估中草药配方和化疗联合疗法抗癌疗效的研究都是在体外或体内进行的:讨论:大多数研究报告了中草药配方与化疗联合治疗在细胞毒性、细胞凋亡和抑制肿瘤生长方面的协同作用。这些作用与细胞周期停滞、抗血管生成和基因表达调控有关。临床试验还需要进一步的研究。东亚国家的临床经验可为今后的研究提供启示。
{"title":"Synergistic and Additive Effects of Herbal Medicines in Combination with Chemotherapeutics: A Scoping Review.","authors":"Taehun Jung, Chunhoo Cheon","doi":"10.1177/15347354241259416","DOIUrl":"10.1177/15347354241259416","url":null,"abstract":"<p><strong>Background: </strong>Natural products are increasingly gaining interest as potential new drug candidates for cancer treatment. Herbal formula, which are combinations of several herbs, are primarily used in East Asia and have a long history of use that continues today. Recently, research exploring the combination of herbal formulas and chemotherapy for cancer treatment has been on the rise.</p><p><strong>Methods: </strong>This study reviewed research on the co-administration of herbal formulas and chemotherapy for cancer treatment. The databases PubMed, Embase, and Cochrane Library were used for article searches. The following keywords were employed: \"Antineoplastic agents,\" \"Chemotherapy,\" \"Phytotherapy,\" \"Herbal medicine,\" \"Drug synergism,\" and \"Synergistic effect.\" The selection process focused on studies that investigated the synergistic interaction between herbal formulas and chemotherapeutic agents.</p><p><strong>Results: </strong>Among the 30 studies included, 25 herbal formulas and 7 chemotherapies were used. The chemotherapy agents co-administered included cisplatin, 5-fluorouracil, docetaxel, doxorubicin, oxaliplatin, irinotecan, and gemcitabine. The types of cancer most frequently studied were lung, breast, and colon cancers. Most studies evaluating the anticancer efficacy of combined herbal formula and chemotherapy treatment were conducted in vitro or in vivo.</p><p><strong>Discussion: </strong>Most studies reported synergistic effects on cytotoxicity, apoptosis, and tumor growth inhibition. These effects were found to be associated with cell cycle arrest, anti-angiogenesis, and gene expression regulation. Further studies leading to clinical trials are required. Clinical experiences in East Asian countries could provide insights for future research.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241259416"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Music Therapy and Music Intervention for NSCLC Patients Undergoing PET with Fear of Cancer Recurrence. 为担心癌症复发而接受 PET 治疗的 NSCLC 患者提供音乐治疗和音乐干预。
IF 2.9 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-01-01 DOI: 10.1177/15347354241269898
Yi-Jie Du, Yi-Hui Guan, Kevin T Thome, Jing-Cheng Dong

Background: Cancer and psychiatric symptoms are associated. Fear of cancer recurrence (FCR) is the most common psychological problem for cancer survivors. Pharmacological interventions can help, but also have major drawbacks. Music therapy and music interventions have been shown to be a safe and practical complementary treatment. Objective: This randomized, controlled trial aimed to investigate the effects of music therapy and music intervention in attenuating non-small cell lung cancer (NSCLC) patients' anxiety related to FCR. Methods: NSCLC patients with FCR were randomly allocated to a music therapy and intervention group (G1) and Control group (G2). Patients' anxiety was measured using the State-Trait Anxiety Inventory scores and heart rates. Primary outcome measure were PET scans. Secondary measures were salivary cortisol, salivary α-amylase levels and heart rate. Findings: Patients in G1 showed higher glucose metabolism of 18F-FDG in the superior frontal gyrus, anterior cingulate, superior temporal gyrus, and parahippocampal gyrus, compared to those in G2 (all P < .001). Heart rates and salivary α-amylase area under the curve (AUC) and relative variation (VAR) in G1 were significantly lower than those in G2 (all P < .05). State-Trait Anxiety Inventory scores and cortisol AUC in G1 were significantly lower than those in G2 (all P < .05). Conclusions: Music therapy and interventions can reduce anxiety and endocrinological responses and change glucose metabolism of 18F-FDG in fear-related brain regions.Trial registration: Registered retrospectively, ISRCTN Registry, www.isrctn.com, ISRCTN23276302Clinical Implications: Cancer treatment centers and physical examination centers should consider providing music therapy and intervention to the appropriate patients as a routine component of a comprehensive clinical care during medical examinations.

背景:癌症与精神症状有关。对癌症复发的恐惧(FCR)是癌症幸存者最常见的心理问题。药物干预可以起到帮助作用,但也有很大的缺点。音乐治疗和音乐干预已被证明是一种安全实用的辅助治疗方法。研究目的本随机对照试验旨在研究音乐疗法和音乐干预对减轻非小细胞肺癌(NSCLC)患者与复发相关的焦虑的效果。方法:将患有 FCR 的非小细胞肺癌患者作为研究对象:将患有 FCR 的 NSCLC 患者随机分配到音乐治疗和干预组(G1)和对照组(G2)。使用状态-特质焦虑量表评分和心率测量患者的焦虑程度。主要结果测量为 PET 扫描。次要测量指标为唾液皮质醇、唾液α-淀粉酶水平和心率。研究结果与 G2 患者相比,G1 患者的额上回、扣带回前部、颞上回和海马旁回的 18F-FDG 糖代谢率更高(均为 P P P 结论:音乐疗法和干预措施可以减轻焦虑:音乐疗法和干预措施可以减轻焦虑和内分泌反应,并改变恐惧相关脑区 18F-FDG 的葡萄糖代谢:回顾性注册,ISRCTN Registry,www.isrctn.com,ISRCTN23276302C 临床意义:癌症治疗中心和体检中心应考虑为适当的患者提供音乐治疗和干预,作为体检期间全面临床护理的常规组成部分。
{"title":"Music Therapy and Music Intervention for NSCLC Patients Undergoing PET with Fear of Cancer Recurrence.","authors":"Yi-Jie Du, Yi-Hui Guan, Kevin T Thome, Jing-Cheng Dong","doi":"10.1177/15347354241269898","DOIUrl":"10.1177/15347354241269898","url":null,"abstract":"<p><p><b>Background:</b> Cancer and psychiatric symptoms are associated. Fear of cancer recurrence (FCR) is the most common psychological problem for cancer survivors. Pharmacological interventions can help, but also have major drawbacks. Music therapy and music interventions have been shown to be a safe and practical complementary treatment. <b>Objective:</b> This randomized, controlled trial aimed to investigate the effects of music therapy and music intervention in attenuating non-small cell lung cancer (NSCLC) patients' anxiety related to FCR. <b>Methods:</b> NSCLC patients with FCR were randomly allocated to a music therapy and intervention group (G1) and Control group (G2). Patients' anxiety was measured using the State-Trait Anxiety Inventory scores and heart rates. Primary outcome measure were PET scans. Secondary measures were salivary cortisol, salivary α-amylase levels and heart rate. <b>Findings:</b> Patients in G1 showed higher glucose metabolism of <sup>18</sup>F-FDG in the superior frontal gyrus, anterior cingulate, superior temporal gyrus, and parahippocampal gyrus, compared to those in G2 (all <i>P</i> < .001). Heart rates and salivary α-amylase area under the curve (AUC) and relative variation (VAR) in G1 were significantly lower than those in G2 (all <i>P</i> < .05). State-Trait Anxiety Inventory scores and cortisol AUC in G1 were significantly lower than those in G2 (all <i>P</i> < .05). <b>Conclusions:</b> Music therapy and interventions can reduce anxiety and endocrinological responses and change glucose metabolism of <sup>18</sup>F-FDG in fear-related brain regions.Trial registration: Registered retrospectively, ISRCTN Registry, www.isrctn.com, ISRCTN23276302Clinical Implications: Cancer treatment centers and physical examination centers should consider providing music therapy and intervention to the appropriate patients as a routine component of a comprehensive clinical care during medical examinations.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241269898"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A single-item Expectancy Measure's Validity, Reliability, and Responsiveness to Detect Changes in Clinical Efficacy Studies of Integrative Cancer Therapies: A Methodology Study. 癌症综合疗法临床疗效研究中检测变化的单项期望测量的有效性、可靠性和响应性:方法论研究。
IF 2.9 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-01-01 DOI: 10.1177/15347354241273944
Anna Efverman

Background: Expectations may modify outcomes. However, studies often fail to measure expectations. This raises the need for a brief valid and reliable expectancy measure.

Objectives: To study treatment expectations in individuals entering acupuncture or rest, validity and test re-test reliability of a single-item expectancy measure graded on a category scale, a Numeric Rating Scale (NRS) and a Visual Analog Scale (VAS), and to identify psychometric differences between the scales.

Method: In this methodology study, treatment expectations were measured in 363 participants before they received acupuncture (genuine traditional penetrating or non-penetrating telescopic sham acupuncture, n = 239, 98%, responded) or a control treatment involving just rest (n = 120, 100%, responded), aimed to improve level of relaxation. A treatment expectancy measure, graded on a five-grade category scale, an eight-grade NRS and a 100 mm VAS, was tested for test re-test reliability. Level of expectation and relaxation was measured at baseline, pre- and post-therapy (n = 729 expectancy measurements).

Results: The participants scheduled for acupuncture or rest believed moderately (Inter Quartile Range, IQR, moderately-much) and much (IQR moderately-much) the treatment to be effective. The Intra-Class Correlation coefficient versus Kappa coefficient between test and re-test was .868/.868 for the category scale, .820/.820 for the NRS, and .856/.854 for the VAS. The middle step "Believe moderately the treatment to be effective" was equivalent with median 4 (IQR, 3-4) on NRS and median 52 mm (IQR 42-52) on VAS. The response rates were 708 (97%) on the category scale, 707 (97%) on the NRS, and 703 (96%) on the VAS. All three scales discriminated that pre-therapy expectations were more positive in the individuals who reported an improvement in relaxation level (P < .001-.003). The VAS presented higher responsiveness to detect expectancy changes over time (71% increased expectation), compared to the NRS (52% increased) and the category scale (12% increased), P < .001.

Conclusions: Individuals entering acupuncture, or a control intervention, presented positive treatment expectations, and the expectancy measure presented satisfactory reliability, validity, high response rates, sensitiveness, and responsiveness. Integrative cancer therapy researchers who want to control for expectancy-related bias in clinical trials should consider measuring expectation using the single-item expectancy measure.

背景:期望可能会改变结果。然而,研究往往无法测量期望值。这就需要一种简短有效且可靠的期望测量方法:研究针灸或静息治疗者的治疗期望、单项期望量表的有效性和重测可靠性,该量表采用分类量表、数字评定量表(NRS)和视觉模拟量表(VAS)进行分级,并确定量表之间的心理测量差异:在这项方法学研究中,363 名参与者在接受针灸(真正的传统透入式或非透入式伸缩假针灸,n = 239,98%,应答)或仅休息的对照治疗(n = 120,100%,应答)之前,对治疗期望进行了测量,目的是提高放松水平。通过五级类别量表、八级 NRS 和 100 毫米 VAS 对治疗期望值进行分级,并对测试再测试的可靠性进行了测试。在基线、治疗前和治疗后对期望和放松程度进行了测量(n = 729 次期望测量):结果:计划接受针灸或休息治疗的受试者对治疗效果的信任度为中度(四分位数间距,IQR,中度-高度)和高度(IQR,中度-高度)。测试与复测之间的类内相关系数与卡帕系数分别为:分类量表为 0.868/.868,NRS 为 0.820/.820,VAS 为 0.856/.854。中间步骤 "适度认为治疗有效 "与 NRS 的中位数 4(IQR,3-4)和 VAS 的中位数 52 毫米(IQR,42-52)相当。分类量表的应答率为 708 (97%),NRS 为 707 (97%),VAS 为 703 (96%)。所有三个量表均显示,报告放松程度有所改善的患者在治疗前的期望值更为积极(P < .001-.003)。与 NRS(增加 52%)和类别量表(增加 12%)相比,VAS 在检测随时间推移的期望值变化方面具有更高的反应性(71% 的期望值增加),P < .001:结论:接受针灸或对照干预的患者都表现出了积极的治疗期望,期望量表具有令人满意的可靠性、有效性、高响应率、敏感性和响应性。希望在临床试验中控制预期相关偏差的癌症综合疗法研究人员应考虑使用单项预期测量法来测量预期。
{"title":"A single-item Expectancy Measure's Validity, Reliability, and Responsiveness to Detect Changes in Clinical Efficacy Studies of Integrative Cancer Therapies: A Methodology Study.","authors":"Anna Efverman","doi":"10.1177/15347354241273944","DOIUrl":"10.1177/15347354241273944","url":null,"abstract":"<p><strong>Background: </strong>Expectations may modify outcomes. However, studies often fail to measure expectations. This raises the need for a brief valid and reliable expectancy measure.</p><p><strong>Objectives: </strong>To study treatment expectations in individuals entering acupuncture or rest, validity and test re-test reliability of a single-item expectancy measure graded on a category scale, a Numeric Rating Scale (NRS) and a Visual Analog Scale (VAS), and to identify psychometric differences between the scales.</p><p><strong>Method: </strong>In this methodology study, treatment expectations were measured in 363 participants before they received acupuncture (genuine traditional penetrating or non-penetrating telescopic sham acupuncture, n = 239, 98%, responded) or a control treatment involving just rest (n = 120, 100%, responded), aimed to improve level of relaxation. A treatment expectancy measure, graded on a five-grade category scale, an eight-grade NRS and a 100 mm VAS, was tested for test re-test reliability. Level of expectation and relaxation was measured at baseline, pre- and post-therapy (n = 729 expectancy measurements).</p><p><strong>Results: </strong>The participants scheduled for acupuncture or rest believed moderately (Inter Quartile Range, IQR, moderately-much) and much (IQR moderately-much) the treatment to be effective. The Intra-Class Correlation coefficient versus Kappa coefficient between test and re-test was .868/.868 for the category scale, .820/.820 for the NRS, and .856/.854 for the VAS. The middle step \"Believe moderately the treatment to be effective\" was equivalent with median 4 (IQR, 3-4) on NRS and median 52 mm (IQR 42-52) on VAS. The response rates were 708 (97%) on the category scale, 707 (97%) on the NRS, and 703 (96%) on the VAS. All three scales discriminated that pre-therapy expectations were more positive in the individuals who reported an improvement in relaxation level (<i>P</i> < .001-.003). The VAS presented higher responsiveness to detect expectancy changes over time (71% increased expectation), compared to the NRS (52% increased) and the category scale (12% increased), <i>P</i> < .001.</p><p><strong>Conclusions: </strong>Individuals entering acupuncture, or a control intervention, presented positive treatment expectations, and the expectancy measure presented satisfactory reliability, validity, high response rates, sensitiveness, and responsiveness. Integrative cancer therapy researchers who want to control for expectancy-related bias in clinical trials should consider measuring expectation using the single-item expectancy measure.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241273944"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of the Herbal Medicine SH003 in Patients With Solid Cancer: A Multi-Center, Single-Arm, Open-Label, Dose-Escalation Phase I Study. 中药 SH003 在实体瘤患者中的安全性:一项多中心、单臂、开放标签、剂量递增的 I 期研究
IF 2.9 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-01-01 DOI: 10.1177/15347354241293451
Chunhoo Cheon, Hyun Woo Lee, Sun Jin Sym, Seong-Gyu Ko

Background: SH003, a novel herbal medicine comprising Huang-Qi, Dang-Gui, and Gua-Lou-Gen, has historical roots in traditional medicine with reported anticancer properties. The need to explore safe and effective treatments in oncology underlines the importance of this study.

Methods: This phase I trial, conducted at Ajou University Hospital and Gachon University Gil Medical Center in Korea, adopted a single-arm, open-label, dose-escalation design. It aimed to evaluate the safety of escalated doses of SH003 in patients with various solid cancers, focusing on determining its maximum tolerated dose. Participants with confirmed solid cancers, unresponsive to standard treatments, were enrolled. The dosage of SH003 was escalated from 4800 to 9600 mg per day, using a 3 + 3 design. Safety was assessed based on the Common Terminology Criteria for Adverse Events ver. 5.0.

Results: The study established that the maximum tolerated dose of SH003 is 9600 mg/day. Most adverse events were mild, primarily including dizziness and nausea, indicating the tolerability of SH003 at this dosage.

Conclusions: SH003 demonstrates safety and promises as an anticancer treatment at doses up to 9600 mg/day. This research supports further investigation into its efficacy for cancer therapy, emphasizing the significance of natural products in oncology, particularly concerning patient safety and tolerance.

背景:SH003是一种由黄芪、当归和瓜蒌根组成的新型中药,在传统医学中具有抗癌的历史渊源。探索安全有效的肿瘤治疗方法的必要性凸显了这项研究的重要性:本 I 期试验在韩国安州大学医院和嘉泉大学吉医疗中心进行,采用单臂、开放标签、剂量递增设计。试验旨在评估SH003在各种实体瘤患者中递增剂量的安全性,重点是确定其最大耐受剂量。研究人员招募了对标准治疗无效的确诊实体瘤患者。采用3+3设计,SH003的剂量从每天4800毫克递增到9600毫克。安全性根据《不良事件通用术语标准》第 5.0 版进行评估。结果:研究确定SH003的最大耐受剂量为9600毫克/天。大多数不良反应都很轻微,主要包括头晕和恶心,这表明SH003在这个剂量下是可以耐受的:结论:SH003作为一种抗癌治疗药物,在最高剂量为9600毫克/天时具有安全性和前景。这项研究支持进一步研究其在癌症治疗中的疗效,强调了天然产品在肿瘤学中的重要性,尤其是在患者的安全性和耐受性方面。
{"title":"Safety of the Herbal Medicine SH003 in Patients With Solid Cancer: A Multi-Center, Single-Arm, Open-Label, Dose-Escalation Phase I Study.","authors":"Chunhoo Cheon, Hyun Woo Lee, Sun Jin Sym, Seong-Gyu Ko","doi":"10.1177/15347354241293451","DOIUrl":"10.1177/15347354241293451","url":null,"abstract":"<p><strong>Background: </strong>SH003, a novel herbal medicine comprising Huang-Qi, Dang-Gui, and Gua-Lou-Gen, has historical roots in traditional medicine with reported anticancer properties. The need to explore safe and effective treatments in oncology underlines the importance of this study.</p><p><strong>Methods: </strong>This phase I trial, conducted at Ajou University Hospital and Gachon University Gil Medical Center in Korea, adopted a single-arm, open-label, dose-escalation design. It aimed to evaluate the safety of escalated doses of SH003 in patients with various solid cancers, focusing on determining its maximum tolerated dose. Participants with confirmed solid cancers, unresponsive to standard treatments, were enrolled. The dosage of SH003 was escalated from 4800 to 9600 mg per day, using a 3 + 3 design. Safety was assessed based on the Common Terminology Criteria for Adverse Events ver. 5.0.</p><p><strong>Results: </strong>The study established that the maximum tolerated dose of SH003 is 9600 mg/day. Most adverse events were mild, primarily including dizziness and nausea, indicating the tolerability of SH003 at this dosage.</p><p><strong>Conclusions: </strong>SH003 demonstrates safety and promises as an anticancer treatment at doses up to 9600 mg/day. This research supports further investigation into its efficacy for cancer therapy, emphasizing the significance of natural products in oncology, particularly concerning patient safety and tolerance.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241293451"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility and Usability of EnergyPoints: A Mobile Health App to Guide Acupressure Use for Cancer Symptom Management. EnergyPoints:指导使用指压疗法控制癌症症状的移动健康应用程序。
IF 2.9 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-01-01 DOI: 10.1177/15347354231223965
Susan L Beck, Ryan Smith, Janet Mindes, Karl Beck, JungYoon Leah Kim, Matthew Weitzman, Jennifer A M Stone, Susan Veleber, William N Dudley

Objective: To examine the feasibility and usability of EnergyPoints™, an innovative mobile health app that teaches and guides people with cancer to implement daily acupressure to self-manage their fatigue and sleep disturbances.

Methods and intervention: The study used an integrated agile, human-centered approach. Adults (age 18 years and over) with cancer experiencing at least moderate fatigue, and living in the Greater New York City community, were recruited from social media, patient advocacy groups, and referrals. Twenty participants (in 3 sprints of 3, 5, and 12) were video-recorded thinking aloud while using the app for the first time. They then used the app at home to self-administer acupressure (twice daily for 1 week) while continuously wearing a fitness tracker. Each participant completed an exit interview and modified Computer System Usability Questionnaire post-participation.

Results: Participants were ages 40 to 76 years and 65% female; 65% were non-Hispanic white. Mean pass rates per ritual exceeded 80%. Users completed (totally or partially) greater than 90% of stimulating acupressure and 70% of relaxing acupressure rituals. Sprint 3 SPs totally completed at least 1 ritual 87% of the time. The majority agreed or strongly agreed the app was easy to use (90%), easy to learn (85%), easy to understand (75%), and effective in helping perform self-acupressure (85%). In an analysis of ease of completing 5 key tasks, all successfully completed the tasks; 3 users required some assistance. Of 654 usability statements, those coded as personal experience/context (197), content related to acupressure learning (105), and content related to the onboarding/profile (71) were most frequent. The design team integrated recommendations into the app before the next sprint.

Conclusions: Findings supported feasibility and usability, as well as acceptability, and led to significant alterations and improvements. EnergyPoints™ offers an opportunity to mainstream acupressure and help cancer survivors self-manage their symptoms.

目的研究 EnergyPoints™ 的可行性和可用性,这是一款创新的移动健康应用程序,可教授并指导癌症患者每天进行穴位按摩,以自我管理疲劳和睡眠障碍:研究采用了以人为本的综合敏捷方法。研究人员通过社交媒体、患者权益组织和转介招募了至少有中度疲劳症状、居住在大纽约市社区的成人癌症患者(18 岁及以上)。对 20 名参与者(3 人、5 人和 12 人)首次使用该应用程序时的大声思考进行了视频录像。然后,他们在家使用该应用程序进行自我穴位按摩(每天两次,持续一周),同时持续佩戴健身追踪器。每位参与者都在参与后完成了退出访谈和修改后的计算机系统可用性问卷调查:参与者年龄在 40 岁至 76 岁之间,65% 为女性;65% 为非西班牙裔白人。每次仪式的平均通过率超过 80%。用户(全部或部分)完成了 90% 以上的刺激性穴位按摩和 70% 以上的放松性穴位按摩仪式。冲刺 3 SP 至少有 87% 的时间完全完成了一个仪式。大多数人同意或非常同意该应用程序易于使用(90%)、易于学习(85%)、易于理解(75%),并能有效帮助进行自我穴位按摩(85%)。在对完成 5 项关键任务的难易程度进行的分析中,所有用户都成功完成了任务;3 名用户需要一些帮助。在 654 项可用性陈述中,个人经历/背景(197 项)、与穴位按摩学习相关的内容(105 项)和与入职/档案相关的内容(71 项)最常见。设计团队在下一次冲刺之前将建议整合到了应用程序中:结论:调查结果支持可行性和可用性以及可接受性,并导致了重大的改变和改进。EnergyPoints™ 为穴位按摩主流化和帮助癌症幸存者自我管理症状提供了机会。
{"title":"Feasibility and Usability of EnergyPoints: A Mobile Health App to Guide Acupressure Use for Cancer Symptom Management.","authors":"Susan L Beck, Ryan Smith, Janet Mindes, Karl Beck, JungYoon Leah Kim, Matthew Weitzman, Jennifer A M Stone, Susan Veleber, William N Dudley","doi":"10.1177/15347354231223965","DOIUrl":"10.1177/15347354231223965","url":null,"abstract":"<p><strong>Objective: </strong>To examine the feasibility and usability of EnergyPoints™, an innovative mobile health app that teaches and guides people with cancer to implement daily acupressure to self-manage their fatigue and sleep disturbances.</p><p><strong>Methods and intervention: </strong>The study used an integrated agile, human-centered approach. Adults (age 18 years and over) with cancer experiencing at least moderate fatigue, and living in the Greater New York City community, were recruited from social media, patient advocacy groups, and referrals. Twenty participants (in 3 sprints of 3, 5, and 12) were video-recorded thinking aloud while using the app for the first time. They then used the app at home to self-administer acupressure (twice daily for 1 week) while continuously wearing a fitness tracker. Each participant completed an exit interview and modified Computer System Usability Questionnaire post-participation.</p><p><strong>Results: </strong>Participants were ages 40 to 76 years and 65% female; 65% were non-Hispanic white. Mean pass rates per ritual exceeded 80%. Users completed (totally or partially) greater than 90% of stimulating acupressure and 70% of relaxing acupressure rituals. Sprint 3 SPs totally completed at least 1 ritual 87% of the time. The majority agreed or strongly agreed the app was easy to use (90%), easy to learn (85%), easy to understand (75%), and effective in helping perform self-acupressure (85%). In an analysis of ease of completing 5 key tasks, all successfully completed the tasks; 3 users required some assistance. Of 654 usability statements, those coded as personal experience/context (197), content related to acupressure learning (105), and content related to the onboarding/profile (71) were most frequent. The design team integrated recommendations into the app before the next sprint.</p><p><strong>Conclusions: </strong>Findings supported feasibility and usability, as well as acceptability, and led to significant alterations and improvements. EnergyPoints™ offers an opportunity to mainstream acupressure and help cancer survivors self-manage their symptoms.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354231223965"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Herbal Combination Shu Gan Jie Yu Regulates the SNCG/ER-a/AKT-ERK Pathway in DMBA-Induced Breast Cancer and Breast Cancer Cell Lines Based on RNA-Seq and IPA Analysis. 基于RNA-Seq和IPA分析的中药复方舒肝解郁调控DMBA诱导的乳腺癌和乳腺癌细胞株的SNCG/ER-a/AKT-ERK通路
IF 2.9 3区 医学 Q1 Medicine Pub Date : 2024-01-01 DOI: 10.1177/15347354241233258
Yi Zhao, Linan Zhao, Tao Wang, Zhenghao Liu, Suyuan Tang, Hongxia Huang, Li Wu, Youzhi Sun

Background: Soothing the liver (called Shu Gan Jie Yu in Chinese, SGJY) is a significant therapeutic method for breast cancer in TCM. In this study, 3 liver-soothing herbs, including Cyperus rotundus L., Citrus medica L. var. sarcodactylis Swingle and Rosa rugosa Thunb. were selected and combined to form a SGJY herbal combinatory.

The aim of the study: To investigate the inhibiting effect of SGJY on breast cancer in vivo and vitro, and to explore the potential mechanisms.

Materials and methods: SGJY herbal combination was extracted using water. A breast cancer rat model was developed by chemical DMBA by gavage, then treated with SGJY for 11 weeks. The tumor tissue was preserved for RNA sequencing and analyzed by IPA software. The inhibition effects of SGJY on MCF-7 and T47D breast cancer cells were investigated by SRB assay and cell apoptosis analysis, and the protein expression levels of SNCG, ER-α, p-AKT and p-ERK were measured by western blotting.

Results: SGJY significantly reduced the tumor weight and volume, and the level of estradiol in serum. The results of IPA analysis reveal SGJY upregulated 7 canonical pathways and downregulated 16 canonical pathways. Estrogen receptor signaling was the key canonical pathway with 9 genes downregulated. The results of upstream regulator analysis reveal beta-estradiol was the central target; the upstream regulator network scheme showed that 86 genes could affect the expression of the beta-estradiol, including SNCG, CCL21 and MB. Additionally, SGJY was verified to significantly alter the expression of SNCG mRNA, CCL21 mRNA and MB mRNA which was consistent with the data of RNA-Seq. The inhibition effects of SGJY exhibited a dose-dependent response. The apoptosis rates of MCF7 and T47D cells were upregulated. The protein expression of SNCG, ER-α, p-AKT and p-ERK were all significantly decreased by SGJY on MCF-7 and T47D cells.

Conclusion: The results demonstrate that SGJY may inhibit the growth of breast cancer. The mechanism might involve downregulating the level of serum estradiol, and suppressing the protein expression in the SNCG/ER-α/AKT-ERK pathway.

背景:舒肝解郁是中医治疗乳腺癌的重要方法。本研究选择了三味舒肝理气的中药,包括香附(Cyperus rotundus L.)、枳壳(Citrus medica L. var. sarcodactylis Swingle)和蔷薇(Rosa rugosa Thunb:研究目的:研究 SGJY 在体内和体外对乳腺癌的抑制作用,并探索其潜在机制:材料和方法:用水提取 SGJY 中药复方。材料和方法:用水提取 SGJY 中药复方制剂,用化学药物 DMBA 灌胃建立乳腺癌大鼠模型,然后用 SGJY 治疗 11 周。保留肿瘤组织进行 RNA 测序,并用 IPA 软件进行分析。采用 SRB 法和细胞凋亡分析法检测 SGJY 对 MCF-7 和 T47D 乳腺癌细胞的抑制作用,并采用 Western 印迹法检测 SNCG、ER-α、p-AKT 和 p-ERK 的蛋白表达水平:结果:SGJY能明显减轻肿瘤的重量和体积,降低血清中雌二醇的水平。IPA分析结果显示,SGJY上调了7条典型通路,下调了16条典型通路。雌激素受体信号转导是关键的典型通路,有 9 个基因被下调。上游调控因子分析结果显示,β-雌二醇是中心靶标;上游调控因子网络方案显示,86 个基因可影响β-雌二醇的表达,包括 SNCG、CCL21 和 MB。此外,SGJY还能显著改变SNCG mRNA、CCL21 mRNA和MB mRNA的表达,这与RNA-Seq的数据一致。SGJY 的抑制作用表现出剂量依赖性。MCF7和T47D细胞的凋亡率上升。SGJY对MCF-7和T47D细胞中SNCG、ER-α、p-AKT和p-ERK的蛋白表达均显著降低:结果表明,SGJY 可抑制乳腺癌的生长。结论:研究结果表明,SGJY 可抑制乳腺癌的生长,其机制可能包括下调血清雌二醇水平,抑制 SNCG/ER-α/AKT-ERK 通路的蛋白表达。
{"title":"The Herbal Combination Shu Gan Jie Yu Regulates the SNCG/ER-a/AKT-ERK Pathway in DMBA-Induced Breast Cancer and Breast Cancer Cell Lines Based on RNA-Seq and IPA Analysis.","authors":"Yi Zhao, Linan Zhao, Tao Wang, Zhenghao Liu, Suyuan Tang, Hongxia Huang, Li Wu, Youzhi Sun","doi":"10.1177/15347354241233258","DOIUrl":"10.1177/15347354241233258","url":null,"abstract":"<p><strong>Background: </strong>Soothing the liver (called <i>Shu Gan Jie Yu</i> in Chinese, SGJY) is a significant therapeutic method for breast cancer in TCM. In this study, 3 liver-soothing herbs, including <i>Cyperus rotundus</i> L., <i>Citrus medica</i> L. var. <i>sarcodactylis</i> Swingle and <i>Rosa rugosa</i> Thunb. were selected and combined to form a SGJY herbal combinatory.</p><p><strong>The aim of the study: </strong>To investigate the inhibiting effect of SGJY on breast cancer in vivo and vitro, and to explore the potential mechanisms.</p><p><strong>Materials and methods: </strong>SGJY herbal combination was extracted using water. A breast cancer rat model was developed by chemical DMBA by gavage, then treated with SGJY for 11 weeks. The tumor tissue was preserved for RNA sequencing and analyzed by IPA software. The inhibition effects of SGJY on MCF-7 and T47D breast cancer cells were investigated by SRB assay and cell apoptosis analysis, and the protein expression levels of SNCG, ER-α, <i>p</i>-AKT and <i>p</i>-ERK were measured by western blotting.</p><p><strong>Results: </strong>SGJY significantly reduced the tumor weight and volume, and the level of estradiol in serum. The results of IPA analysis reveal SGJY upregulated 7 canonical pathways and downregulated 16 canonical pathways. Estrogen receptor signaling was the key canonical pathway with 9 genes downregulated. The results of upstream regulator analysis reveal beta-estradiol was the central target; the upstream regulator network scheme showed that 86 genes could affect the expression of the beta-estradiol, including SNCG, CCL21 and MB. Additionally, SGJY was verified to significantly alter the expression of SNCG mRNA, CCL21 mRNA and MB mRNA which was consistent with the data of RNA-Seq. The inhibition effects of SGJY exhibited a dose-dependent response. The apoptosis rates of MCF7 and T47D cells were upregulated. The protein expression of SNCG, ER-α, <i>p</i>-AKT and <i>p</i>-ERK were all significantly decreased by SGJY on MCF-7 and T47D cells.</p><p><strong>Conclusion: </strong>The results demonstrate that SGJY may inhibit the growth of breast cancer. The mechanism might involve downregulating the level of serum estradiol, and suppressing the protein expression in the SNCG/ER-α/AKT-ERK pathway.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241233258"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10878215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of Herbal Medicinal Plants Used in the Management of Cancers in the East Africa Region from 2019 to 2023. 2019年至2023年东非地区用于治疗癌症的草本药用植物回顾。
IF 2.9 3区 医学 Q1 Medicine Pub Date : 2024-01-01 DOI: 10.1177/15347354241235583
Ali Kudamba, Josephine N Kasolo, Godfrey S Bbosa, Allan Lugaajju, Henry Wabinga, Hussein M Kafeero, Jamilu E Ssenku, Shaban O Alemu, Abdul Walusansa, Nixon Niyonzima, Haruna Muwonge

Background: In the East African region, herbal plants are essential in the treatment and control of cancer. Given the diverse ecological and cultural makeup of the regional states, it is likely that different ethnic groups will use the same or different plants for the same or different diseases. However, since 2019, this has not been compiled into a single study.

Purpose: The study aimed to compile and record the medicinal plants utilized in East Africa from April 2019 to June 2023 to treat various cancer types.

Materials and methods: The study examined 13 original studies that included ethnobotanical research conducted in East Africa. They were retrieved from several internet databases, including Google Scholar, Scopus, PubMed/Medline, Science Direct, and Research for Life. The study retrieved databases on plant families and species, plant parts used, preparation methods and routes of administration, and the country where the ethnobotanical field surveys were conducted. Graphs were produced using the GraphPad Prism 8.125 program (GraphPad Software, Inc., San Diego, CA). Tables and figures were used to present the data, which had been condensed into percentages and frequencies.

Results: A total of 105 different plant species from 45 different plant families were identified, including Asteraceae (14), Euphorbiaceae (12), Musaceae (8), and Apocynaceae (7). Uganda registered the highest proportion (46% of the medicinal plants used). The most commonly mentioned medicinal plant species in cancer management was Prunus africana. Herbs (32%), trees and shrubs (28%), and leaves (45%) constituted the majority of herbal remedies. Most herbal remedies were prepared by boiling (decoction) and taken orally (57%).

Conclusion: East Africa is home to a wide variety of medicinal plant species that local populations and herbalists, or TMP, frequently use in the treatment of various types of cancer. The most frequently used families are Asteraceae and Euphorbiaceae, with the majority of species being found in Uganda. The most frequently utilized plant species is Prunus africana. Studies on the effectiveness of Prunus africana against other malignancies besides prostate cancer are required.

背景:在东非地区,草本植物对治疗和控制癌症至关重要。由于该地区各州的生态和文化构成各不相同,不同的种族群体很可能会使用相同或不同的植物来治疗相同或不同的疾病。然而,自 2019 年以来,这方面的情况尚未汇编成一份研究报告。目的:本研究旨在汇编和记录 2019 年 4 月至 2023 年 6 月期间东非地区用于治疗各种癌症的药用植物:本研究审查了 13 项原创研究,其中包括在东非开展的人种植物学研究。这些研究是从多个互联网数据库中检索的,包括谷歌学术、Scopus、PubMed/Medline、Science Direct 和 Research for Life。研究检索了有关植物科和种、所用植物部位、制备方法和给药途径以及进行民族植物学实地调查的国家的数据库。使用 GraphPad Prism 8.125 程序(GraphPad Software, Inc.)数据用表格和数字表示,并浓缩成百分比和频率:共鉴定出 45 个不同植物科的 105 种不同植物,包括菊科(14 种)、大戟科(12 种)、蕈科(8 种)和天南星科(7 种)。乌干达的比例最高(占所用药用植物的 46%)。在癌症治疗中最常提及的药用植物种类是非洲李(Prunus africana)。草药(32%)、乔木和灌木(28%)以及树叶(45%)占草药疗法的大多数。大多数草药通过煮沸(煎煮)后口服(57%):结论:东非是多种药用植物的故乡,当地居民和草药医生(TMP)经常使用这些植物治疗各种癌症。最常使用的植物科是菊科和大戟科,大部分物种在乌干达发现。最常用的植物物种是非洲李。除前列腺癌外,还需要研究非洲李对其他恶性肿瘤的疗效。
{"title":"Review of Herbal Medicinal Plants Used in the Management of Cancers in the East Africa Region from 2019 to 2023.","authors":"Ali Kudamba, Josephine N Kasolo, Godfrey S Bbosa, Allan Lugaajju, Henry Wabinga, Hussein M Kafeero, Jamilu E Ssenku, Shaban O Alemu, Abdul Walusansa, Nixon Niyonzima, Haruna Muwonge","doi":"10.1177/15347354241235583","DOIUrl":"10.1177/15347354241235583","url":null,"abstract":"<p><strong>Background: </strong>In the East African region, herbal plants are essential in the treatment and control of cancer. Given the diverse ecological and cultural makeup of the regional states, it is likely that different ethnic groups will use the same or different plants for the same or different diseases. However, since 2019, this has not been compiled into a single study.</p><p><strong>Purpose: </strong>The study aimed to compile and record the medicinal plants utilized in East Africa from April 2019 to June 2023 to treat various cancer types.</p><p><strong>Materials and methods: </strong>The study examined 13 original studies that included ethnobotanical research conducted in East Africa. They were retrieved from several internet databases, including Google Scholar, Scopus, PubMed/Medline, Science Direct, and Research for Life. The study retrieved databases on plant families and species, plant parts used, preparation methods and routes of administration, and the country where the ethnobotanical field surveys were conducted. Graphs were produced using the GraphPad Prism 8.125 program (GraphPad Software, Inc., San Diego, CA). Tables and figures were used to present the data, which had been condensed into percentages and frequencies.</p><p><strong>Results: </strong>A total of 105 different plant species from 45 different plant families were identified, including Asteraceae (14), Euphorbiaceae (12), Musaceae (8), and Apocynaceae (7). Uganda registered the highest proportion (46% of the medicinal plants used). The most commonly mentioned medicinal plant species in cancer management was <i>Prunus africana</i>. Herbs (32%), trees and shrubs (28%), and leaves (45%) constituted the majority of herbal remedies. Most herbal remedies were prepared by boiling (decoction) and taken orally (57%).</p><p><strong>Conclusion: </strong>East Africa is home to a wide variety of medicinal plant species that local populations and herbalists, or TMP, frequently use in the treatment of various types of cancer. The most frequently used families are Asteraceae and Euphorbiaceae, with the majority of species being found in Uganda. The most frequently utilized plant species is <i>Prunus africana</i>. Studies on the effectiveness of <i>Prunus africana</i> against other malignancies besides prostate cancer are required.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"23 ","pages":"15347354241235583"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10916491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Integrative Cancer Therapies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1